Literature DB >> 22058177

A study of the natural history of diabetic kidney disease (DKD).

Nagi Altemtam1, Jean Russell, Meguid El Nahas.   

Abstract

BACKGROUND: In view of the alarming increase in the number of people with diabetes mellitus (DM), a rising number of patients with diabetic kidney disease (DKD), end-stage renal disease (ESRD) and cardiovascular disease (CVD) is forecasted. It is therefore imperative to re-visit the natural history of DKD and to identify potential risk factors, which may enhance the progression of the disease and its complications.
METHODS: The medical records of 270 Type 2 diabetic chronic kidney disease patients followed up at the Sheffield Kidney Institute between 2000 and 2008 were reviewed. Various socio-demographic, clinical and biochemical parameters (baseline and follow-up parameters) were retrospectively collected from the patients' database. Progression of DKD was evaluated by evaluation of the rate of decline of estimated glomerular filtration rate (eGFR) as calculated from the simplified Modification of Diet in Renal Disease formula [progressors: loss of glomerular filtration rate (GFR) >2 mL/min/1.73m(2)/year] as well as by the progression pattern based on the slope of GFR changes. Variables associated with progression in univariate analysis were examined by multivariate analysis to determine the factors independently associated with DKD progression.
RESULTS: The majority of the study populations were males (66.7%) and Caucasians (88%). Ninety-four patients (34.8%) had progressive, whereas 176 (65.2%) had non-progressive DKD. The rate of eGFR decline in progressors was -3.57 ± 1.45 mL/min/1.73m(2)/year compared to -1.31 ± 0.23 mL/min/1.73m(2)/year in non-progressors. The following parameters discriminated progressors from non-progressors by univariate analysis: baseline-blood pressure (BP) parameters, eGFR and proteinuria as well as serum uric acid. We also observed that area under the curve for follow-up systolic blood pressure (SBP), glycosylated haemoglobin (HbA1c) and proteinuria were significantly higher among the progressors (P = 0.043, P = 0.02 and P = 0.001, respectively). Independent determinants of DKD progression in this study in an adjusted logistic regression model were baseline HbA1c [odds ratio (OR), 2.27; 95% confidence interval (CI), 1.14-4.54], baseline SBP (OR, 1.23; 95% CI, 1.06-1.41), baseline proteinuria (OR, 3.24; 95% CI, 2.1-5.38), baseline serum uric acid (OR, 1.16; 95% CI, 1.09-1.39) and vascular co-morbidities (OR, 1.61; 95% CI, 1.02-2.54). Percentage changes in the key parameters (BP, HbA1c and proteinuria) during the first year of the study did not affect the rate of eGFR decline.
CONCLUSIONS: Baseline HbA1c, SBP, proteinuria and serum uric acid together with the presence of vascular co-morbidities are strongly and independently associated with faster DKD progression. A further prospective observational study is currently undertaken to evaluate these findings and to determine the predictive value of other biochemical peptides and cellular markers on DKD outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22058177     DOI: 10.1093/ndt/gfr561

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  49 in total

Review 1.  Fructose and uric acid in diabetic nephropathy.

Authors:  Petter Bjornstad; Miguel A Lanaspa; Takuji Ishimoto; Tomoki Kosugi; Shinji Kume; Diana Jalal; David M Maahs; Janet K Snell-Bergeon; Richard J Johnson; Takahiko Nakagawa
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

Review 2.  Hyperuricemia and Hypertension: Links and Risks.

Authors:  Douglas J Stewart; Valerie Langlois; Damien Noone
Journal:  Integr Blood Press Control       Date:  2019-12-24

3.  Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m2 and negative proteinuria.

Authors:  Fangfang Zhou; Geping Yu; Guoyu Wang; Yunzi Liu; Liwen Zhang; Weiming Wang; Nan Chen
Journal:  Clin Exp Nephrol       Date:  2019-02-08       Impact factor: 2.801

Review 4.  Renal dysfunction and chronic mechanical circulatory support: from patient selection to long-term management and prognosis.

Authors:  Meredith A Brisco; Jeffrey M Testani; Jennifer L Cook
Journal:  Curr Opin Cardiol       Date:  2016-05       Impact factor: 2.161

Review 5.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

6.  Poor glycaemic control and its metabolic and demographic risk factors in a Malaysian community-based study.

Authors:  Daniel D Reidpath; Ireneous Soyiri; Nowrozy K Jahan; Devi Mohan; Badariah Ahmad; Mohtar Pungut Ahmad; Zaid Bin Kassim; Pascale Allotey
Journal:  Int J Public Health       Date:  2018-01-25       Impact factor: 3.380

7.  Factors affecting the progression of renal dysfunction and the importance of salt restriction in patients with type 2 diabetic kidney disease.

Authors:  Noriko Kanauchi; Susumu Ookawara; Kiyonori Ito; Satsuki Mogi; Izumi Yoshida; Masafumi Kakei; San-E Ishikawa; Yoshiyuki Morishita; Kaoru Tabei
Journal:  Clin Exp Nephrol       Date:  2015-04-29       Impact factor: 2.801

8.  Mendelian randomization analysis indicates serum urate has a causal effect on renal function in Chinese women.

Authors:  Jing Liu; Hui Zhang; Zheng Dong; Jingru Zhou; Yanyun Ma; Yuan Li; Qiaoxia Qian; Ziyu Yuan; Juan Zhang; Yajun Yang; Xiaofeng Wang; Xingdong Chen; Hejian Zou; Li Jin; Jiucun Wang
Journal:  Int Urol Nephrol       Date:  2017-08-30       Impact factor: 2.370

9.  Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Chunze Zhou; Ruifeng Wang; Yikun Ding; Linan Du; Changlong Hou; Dong Lu; Li Hao; Weifu Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

10.  Fructose tolerance test in obese people with and without type 2 diabetes.

Authors:  Ebaa Al-Ozairi; Christopher J Rivard; Laura Gabriela Sanchez Lozada; Miguel A Lanaspa; Petter Bjornstad; Danah Al Salem; Asma Alhubail; Amira Megahed; Masanari Kuwabara; Richard J Johnson; Reem A Asad
Journal:  J Diabetes       Date:  2019-09-18       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.